Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for X-396

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients


    Print this page for your doctor